These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38769817)

  • 1. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors.
    Fukushima T; Kobayashi S; Ueno M
    Jpn J Clin Oncol; 2024 Sep; 54(9):949-958. PubMed ID: 38769817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database.
    Asano H; Noguchi Y; Kimura M; Usami E; Yoshimura T
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004012
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.
    Trinh S; Le A; Gowani S; La-Beck NM
    Asia Pac J Oncol Nurs; 2019; 6(2):154-160. PubMed ID: 30931360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
    Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
    Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.
    Zhou YW; Xu Q; Wang Y; Xia RL; Liu JY; Ma XL
    Int J Ophthalmol; 2022; 15(4):646-656. PubMed ID: 35450191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 8. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
    Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
    Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Managing the Adverse Effects Related to Immune Checkpoint Inhibitors].
    Kuo HH; Chen WW
    Hu Li Za Zhi; 2018 Jun; 65(3):88-95. PubMed ID: 29790143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
    Möhn N; Beutel G; Gutzmer R; Ivanyi P; Satzger I; Skripuletz T
    J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31653079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
    Stenehjem D; Lubinga SJ; Wu A; Betts KA
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
    Morse MA; Hochster H; Benson A
    Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.